AiCure

Awards & Advancement

Cloud Pharmaceuticals ratifies board of directors

Friday, November 7, 2014 01:42 PM

Cloud Pharmaceuticals, a therapeutics company focused on cloud-based drug design and development, has ratified its board of directors. Members of the board include Cloud Pharmaceuticals chairman and CEO Ed Addison, chief scientific officer Shahar Keinan, Ph.D., and chief information officer Lawrence Husick. Other members of the board include:

More... »


Lexicon expands management

Thursday, November 6, 2014 03:13 PM

Lexicon Pharmaceuticals has announced management additions directed toward the completion of phase III development and commercial preparations for telotristat etiprate in carcinoid syndrome and preparation for phase III initiation and commercial readiness for sotagliflozin (LX4211) in type 1 diabetes.

More... »

Subscribe to The CenterWatch Monthly

CluePoints wins ENTENTE Life Science Investment Forum Award

Thursday, October 30, 2014 01:32 PM

CluePoints, a provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, has secured an ENTENTE Life Science Investment Forum Award. The award program, which is organized by the ENTENTE project and supported by the European Commission and EuropaBio, recognized CluePoints as one of Belgium's most innovative high technology businesses for its Central Statistical Monitoring (CSM) solution, which employs unique statistical algorithms to determine the quality, accuracy and integrity of clinical trial data.

More... »

ERT named innovation award recipient by Philadelphia Business Journal

Monday, October 27, 2014 01:32 PM

ERT, a global solution provider for high-quality patient safety and efficacy endpoint data collection, has been honored as a 2014 Innovation Award Recipient by the Philadelphia Business Journal. The awards program recognizes the region’s leading companies for their innovations in the fields of healthcare and life sciences.

More... »

Synchrogenix appoints two new global submissions directors

Monday, October 27, 2014 01:30 PM

Synchrogenix Information Strategies, a regulatory writing company headquartered in Wilmington, Del., has added two new global submissions directors: Kelley Hill and Aaron Bernstein.

More... »

Cubist Pharmaceuticals names Robert J. Perez CEO

Thursday, October 23, 2014 03:47 PM

Cubist Pharmaceuticals has selected Robert J. Perez as the company's CEO, effective January, 2015. Perez, who currently is Cubist's president and chief operating officer, will succeed Michael W. Bonney who is retiring from his current role as CEO on Dec. 31, and will become non-executive chair of Cubist's board of directors. Current board chair Kenneth M. Bate will become lead independent director.

More... »

ProNAi Therapeutics adds five to senior management team

Thursday, October 23, 2014 03:17 PM

ProNAi Therapeutics, a private company dedicated to developing and commercializing a new class of therapies based on its proprietary DNAi platform, has added five seasoned executives to its senior management team.

More... »

aTyr Pharma appoints John C. McKew vice president, research

Thursday, October 23, 2014 01:45 PM

aTyr Pharma, an innovative rare disease therapeutics enterprise, has announced that John C. McKew, Ph.D., has joined the company as vice president, research. McKew brings more than two decades of experience in translational research, including key leadership positions at the NIHWyeth Research and Genetics Institute (prior to its acquisition by Wyeth). McKew will lead aTyr's efforts to expand and translate its novel Physiocrine biology into meaningful therapeutics to treat rare, grave immune-driven disorders.

More... »

Synthetic Biologics fills irritable bowel syndrome Clinical Advisory Board

Thursday, October 16, 2014 12:29 PM

Synthetic Biologics, a biotechnology company developing novel anti-infective biologics and drugs targeting specific pathogens that cause serious infections and diseases, has expanded its Clinical Advisory Board (CAB) created to support development of SYN-010, the company's statin-class candidate intended to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS).

More... »

CytRx appoints Steven A. Kriegsman as chairman of the board

Thursday, October 16, 2014 12:21 PM

CytRx, a biopharmaceutical R&D company specializing in oncology, has appointed Steven A. Kriegsman, president, CEO and a director of the company, as chairman of the board, effective Oct. 15. He replaces Max E. Link, Ph.D., whose unexpected passing was announced on Oct. 7.

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs